Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future - PubMed
5 hours ago
- #LDL cholesterol
- #cardiovascular outcomes
- #PCSK9 inhibitors
- PCSK9 inhibitors were developed based on genetic discoveries as a new class of LDL cholesterol-lowering drugs.
- These inhibitors are as potent as high-intensity statins and have an excellent safety profile.
- Clinical trials have shown PCSK9 inhibitors reduce major adverse cardiovascular outcomes in various patient groups, including those with prior ASCVD events, atherosclerosis without major ASCVD events, and diabetes.
- Lowering LDL cholesterol to ≤1 mmol/L (≤40 mg/dL) has demonstrated clinical benefits.
- New PCSK9 inhibitor variants under study include oral inhibitors, RNA interference, and gene therapy.